1. Home
  2. MLYS vs BLND Comparison

MLYS vs BLND Comparison

Compare MLYS & BLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • BLND
  • Stock Information
  • Founded
  • MLYS 2019
  • BLND 2012
  • Country
  • MLYS United States
  • BLND United States
  • Employees
  • MLYS N/A
  • BLND N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • BLND EDP Services
  • Sector
  • MLYS Health Care
  • BLND Technology
  • Exchange
  • MLYS Nasdaq
  • BLND Nasdaq
  • Market Cap
  • MLYS 893.0M
  • BLND 815.3M
  • IPO Year
  • MLYS 2023
  • BLND 2021
  • Fundamental
  • Price
  • MLYS $13.35
  • BLND $3.11
  • Analyst Decision
  • MLYS Strong Buy
  • BLND Buy
  • Analyst Count
  • MLYS 3
  • BLND 8
  • Target Price
  • MLYS $33.00
  • BLND $4.66
  • AVG Volume (30 Days)
  • MLYS 1.3M
  • BLND 3.5M
  • Earning Date
  • MLYS 05-08-2025
  • BLND 05-08-2025
  • Dividend Yield
  • MLYS N/A
  • BLND N/A
  • EPS Growth
  • MLYS N/A
  • BLND N/A
  • EPS
  • MLYS N/A
  • BLND N/A
  • Revenue
  • MLYS N/A
  • BLND $162,019,000.00
  • Revenue This Year
  • MLYS N/A
  • BLND $15.07
  • Revenue Next Year
  • MLYS N/A
  • BLND $21.95
  • P/E Ratio
  • MLYS N/A
  • BLND N/A
  • Revenue Growth
  • MLYS N/A
  • BLND 3.30
  • 52 Week Low
  • MLYS $8.24
  • BLND $2.08
  • 52 Week High
  • MLYS $18.38
  • BLND $5.53
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 49.65
  • BLND 38.84
  • Support Level
  • MLYS $10.44
  • BLND $3.05
  • Resistance Level
  • MLYS $14.83
  • BLND $3.25
  • Average True Range (ATR)
  • MLYS 1.49
  • BLND 0.25
  • MACD
  • MLYS -0.14
  • BLND -0.02
  • Stochastic Oscillator
  • MLYS 43.24
  • BLND 24.39

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.

Share on Social Networks: